Oncoclínicas do Brasil Serviços Médicos Management
Management criteria checks 1/4
Oncoclínicas do Brasil Serviços Médicos' CEO is Bruno Ferrari, appointed in Jan 2010, has a tenure of 14.83 years. directly owns 8.65% of the company’s shares, worth R$243.00M. The average tenure of the management team and the board of directors is 2.6 years and 0.8 years respectively.
Key information
Bruno Ferrari
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 14.8yrs |
| CEO ownership | 8.7% |
| Management average tenure | 2.6yrs |
| Board average tenure | less than a year |
Recent management updates
Recent updates
With A 25% Price Drop For Oncoclínicas do Brasil Serviços Médicos S.A. (BVMF:ONCO3) You'll Still Get What You Pay For
Sep 27
Here's What Analysts Are Forecasting For Oncoclínicas do Brasil Serviços Médicos S.A. (BVMF:ONCO3) After Its Second-Quarter Results
Aug 15Oncoclínicas do Brasil Serviços Médicos (BVMF:ONCO3) Takes On Some Risk With Its Use Of Debt
Aug 13Earnings Tell The Story For Oncoclínicas do Brasil Serviços Médicos S.A. (BVMF:ONCO3) As Its Stock Soars 27%
Jul 16Is Now An Opportune Moment To Examine Oncoclínicas do Brasil Serviços Médicos S.A. (BVMF:ONCO3)?
Jul 03Investors Appear Satisfied With Oncoclínicas do Brasil Serviços Médicos S.A.'s (BVMF:ONCO3) Prospects As Shares Rocket 25%
Jun 01Oncoclínicas do Brasil Serviços Médicos S.A.'s (BVMF:ONCO3) Share Price Is Still Matching Investor Opinion Despite 27% Slump
Apr 17Oncoclínicas do Brasil Serviços Médicos' (BVMF:ONCO3) Earnings Are Weaker Than They Seem
Apr 03Oncoclínicas do Brasil Serviços Médicos (BVMF:ONCO3) Has A Somewhat Strained Balance Sheet
Mar 11What Does Oncoclínicas do Brasil Serviços Médicos S.A.'s (BVMF:ONCO3) Share Price Indicate?
Feb 17It's A Story Of Risk Vs Reward With Oncoclínicas do Brasil Serviços Médicos S.A. (BVMF:ONCO3)
Dec 08Why Oncoclínicas do Brasil Serviços Médicos S.A. (BVMF:ONCO3) Could Be Worth Watching
Nov 06Is Now The Time To Put Oncoclínicas do Brasil Serviços Médicos (BVMF:ONCO3) On Your Watchlist?
Sep 11Oncoclínicas do Brasil Serviços Médicos S.A. (BVMF:ONCO3) Just Reported Earnings, And Analysts Cut Their Target Price
Apr 03CEO
Bruno Ferrari
14.8yrs
Tenure
Mr. Bruno Lemos Ferrari is CEO and Director of Oncoclínicas do Brasil Serviços Médicos S.A. from 2010 and serves as its Vice Chairman since May 2022. Mr. Ferrari is full member of the Brazilian Society of...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Vice Chairman & CEO | 14.8yrs | no data | 8.65% R$ 243.0m | |
| Chief Financial and Investor Relations Officer | 2.6yrs | no data | no data | |
| Director of M&A and Operations | less than a year | no data | no data | |
| Chief Technology Officer | 2.8yrs | no data | no data | |
| Director of Compliance & Legal | no data | no data | no data | |
| Marketing Officer | no data | no data | no data | |
| Human Resources Officer | no data | no data | no data | |
| Chief Strategy Officer & Board Member | less than a year | no data | no data |
2.6yrs
Average Tenure
Experienced Management: ONCO3's management team is considered experienced (2.6 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Vice Chairman & CEO | 14.8yrs | no data | 8.65% R$ 243.0m | |
| Chief Financial and Investor Relations Officer | less than a year | no data | no data | |
| Chief Strategy Officer & Board Member | no data | no data | no data | |
| Member of Fiscal Council | less than a year | no data | no data | |
| Chairman | no data | no data | no data | |
| Director | 2.5yrs | no data | no data | |
| President of the Fiscal Council | 1.8yrs | no data | no data | |
| Board Member | no data | no data | no data | |
| Board Member | less than a year | no data | no data | |
| Board Member | no data | no data | no data | |
| Board Member | no data | no data | no data | |
| Independent Director | less than a year | no data | no data |
0.8yrs
Average Tenure
59.5yo
Average Age
Experienced Board: ONCO3's board of directors are not considered experienced ( 0.8 years average tenure), which suggests a new board.